systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-364Research ArticleКАРДИОЛОГИЯCARDIOLOGYВозможности блокаторов рецепторов ангиотензина II (сартанов) у больных артериальной гипертензиейPossibilities ARB II (sartans) in hypertensive patientsМорозоваТ. Е.MorozovaT. E.temorozova@gmail.comАндрущишинаТ. Б.AndrushchishinaT. B.tbraeva@gmail.comГонтаренкоС. В.GontarenkoS. V.svetaovch@mail.ruГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова, РоссияРоссия2014231220221133338Copyright © Морозова Т.Е., Андрущишина Т.Б., Гонтаренко С.В., 20222022Морозова Т.Е., Андрущишина Т.Б., Гонтаренко С.В.Morozova T.E., Andrushchishina T.B., Gontarenko S.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/364

Ангиотензина II (БРА), неоднородная группа препаратов, представители которой имеют существенные внутригрупповые различия. В данной статье сделан акцент на свойствах и эффектах олмесартана, которые выделяют его среди прочих БРА. Наряду с выраженным долгосрочным антигипертензивным действием олмесартан обладает органопротективными свойствами (вызывает обратное развитие гипертрофии левого желудочка, оказывает нефропротекцию и пр.). Опыт клинического применения олмесартана свидетельствует о высокой эффективности и хорошем спектре безопасности у разных категорий больных АГ.

The article presents an overview of the literature on the choice of pharmacotherapy of arterial hypertension (AH). Among antihypertensive drugs occupy an important place ARBs II (BRA), a heterogeneous group of drugs whose representatives have significant intercompany differences. This article focuses on the properties and effects of olmesartan, that distinguish it from other ARBs. Along with a strong long-term antihypertensive effect of olmesartan has organoprotective (regression of LVH, nephroprotection etc.). Olmesartan clinical experience indicates a high efficiency and a good range of security among different categories of patients with hypertension.

сердечно-сосудистые заболеванияартериальная гипертензияфармакотерапия АГантигипертензивная терапияренин-ангиотензин-альдостероновая системаРААСблокаторы рецепторов ангиотензина IIБРАолмесартанкардосалклинические исследованияобзорсardosalcardiovascular diseasehypertensionpharmacotherapy of hypertensionantihypertensive therapythe renin-angiotensin-aldosterone systemRAASangiotensin receptor IIARBsolmesartanclinical studiesreviewReferencesPereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27: 963-75.Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27: 963-75.Britton K.A, Gaziano J.M, Djousse L. Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail 2009; 11: 1129-34.Britton K.A, Gaziano J.M, Djousse L. Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail 2009; 11: 1129-34.Redon J, Olsen M.H, Cooper R.S et al. Stroke mortality trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J 2011; 32: 1424-31.Redon J, Olsen M.H, Cooper R.S et al. Stroke mortality trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J 2011; 32: 1424-31.ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-357.ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-357.Диагностика и лечение артериальной гипертонии. Клин. рекомендации Минздрава РФ, 2013; http://cardioweb.ru/klinicheskie-rekomendatsiiДиагностика и лечение артериальной гипертонии. Клин. рекомендации Минздрава РФ, 2013; http://cardioweb.ru/klinicheskie-rekomendatsiiHaralambos P, Gavras, Salernob C.M. The angiotensin II Type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 1996; 18 (6): 1058-67.Haralambos P, Gavras, Salernob C.M. The angiotensin II Type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 1996; 18 (6): 1058-67.Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 18S-24S.Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 18S-24S.Edwards R.M, Aiyar N, Ohlstein E.H et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992; 260: 175-81.Edwards R.M, Aiyar N, Ohlstein E.H et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992; 260: 175-81.Israili Z.H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): S73-86.Israili Z.H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): S73-86.Puig J.G et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999; 17: 1033-9.Puig J.G et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999; 17: 1033-9.Wurzner C et al. Comparative effects of losartan and ibresartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855-60.Wurzner C et al. Comparative effects of losartan and ibresartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855-60.Pitt B et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.Pitt B et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.Brenner B.M, Cooper M.E, de Zeeuw D et al. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). N Engl J Med 2001; 345: 861-9.Brenner B.M, Cooper M.E, de Zeeuw D et al. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). N Engl J Med 2001; 345: 861-9.Julius S, Kjeldsen S.E et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE. Lancet 2004; 363: 2022-31.Julius S, Kjeldsen S.E et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE. Lancet 2004; 363: 2022-31.Granger C.B, Mc Murray J.J.V et al. Effects of candesartan in patients with chronic heart failure and reduced left - ventricular systolic function intolerant to angiotensin - converting - enzyme inhibitors: the CHARM- Alternative trial Lancet 2003; 362: 772-6.Granger C.B, Mc Murray J.J.V et al. Effects of candesartan in patients with chronic heart failure and reduced left - ventricular systolic function intolerant to angiotensin - converting - enzyme inhibitors: the CHARM- Alternative trial Lancet 2003; 362: 772-6.Warner G.T, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 (9): 1345-53; discussion 1354-6.Warner G.T, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 (9): 1345-53; discussion 1354-6.Von Bergmann K, Laeis P, Püchler K et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001; 19 (Suppl. 1): S33-S40.Von Bergmann K, Laeis P, Püchler K et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001; 19 (Suppl. 1): S33-S40.Puchler К, Laeis Р, Witte P.U, Brunner H.R. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotesin II antagonist, in salt - restricted hypertensive patients. J Hypertens 1997; 15 (2): 1809-12.Puchler К, Laeis Р, Witte P.U, Brunner H.R. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotesin II antagonist, in salt - restricted hypertensive patients. J Hypertens 1997; 15 (2): 1809-12.Puchler К, Laeis Р, Stumpe К.О. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 (Suppl. 1): 41-8.Puchler К, Laeis Р, Stumpe К.О. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 (Suppl. 1): 41-8.Van Mieghem W. A multi - centre, double - blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension (Abstract). J Hypertens 2001; 19 (Suppl. 1): S152.Van Mieghem W. A multi - centre, double - blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension (Abstract). J Hypertens 2001; 19 (Suppl. 1): S152.Ball K.J, Williams P.A, Stumpe K.O. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19 (Suppl. 1): S49-S56.Ball K.J, Williams P.A, Stumpe K.O. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19 (Suppl. 1): S49-S56.Chrysant S.G, Marbury T. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mildt - moderate hypertension. Am J Hypertens 2002; 15: A57 (Abstract).Chrysant S.G, Marbury T. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mildt - moderate hypertension. Am J Hypertens 2002; 15: A57 (Abstract).David H.G, Smith. Strategies to Meet Lower Blood Pressure Goals With a New Standard in Angiotensin II Receptor Blockade. Am J Hypertens 2002; 15: 108-14.David H.G, Smith. Strategies to Meet Lower Blood Pressure Goals With a New Standard in Angiotensin II Receptor Blockade. Am J Hypertens 2002; 15: 108-14.Brunner H.R, Laeise Р. Сlinical efficacy of olmesartan medoxomil. J Hypertens 2003; 21 (2): 43-6.Brunner H.R, Laeise Р. Сlinical efficacy of olmesartan medoxomil. J Hypertens 2003; 21 (2): 43-6.David H.G, Smith, Dubiel R, Jones M. Use of 24-hour ambulatory plod pressure monitoring to assess antihypertensive efficacy. A comparison of olmesartan medoxomil, losartan potassium, valsartan and irbesartan. Am J Cardiovasc Drugs 2005; 5 (1): 41-50.David H.G, Smith, Dubiel R, Jones M. Use of 24-hour ambulatory plod pressure monitoring to assess antihypertensive efficacy. A comparison of olmesartan medoxomil, losartan potassium, valsartan and irbesartan. Am J Cardiovasc Drugs 2005; 5 (1): 41-50.Brunner H.R, Arakawa К. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Invest 2006; 26 (4): 185-93.Brunner H.R, Arakawa К. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Invest 2006; 26 (4): 185-93.Ritz E, Viberti G.C, Ruilope L.M et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53 (1): 49-57.Ritz E, Viberti G.C, Ruilope L.M et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53 (1): 49-57.Minatoguchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan on early morning hypertension and heart rate. Blood Press 2013.Minatoguchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan on early morning hypertension and heart rate. Blood Press 2013.Arao T, Okada Y, Mori H et al. Antihypertensive and methabolic effects of high - dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J 2013.Arao T, Okada Y, Mori H et al. Antihypertensive and methabolic effects of high - dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J 2013.Hirohata A, Yamamoto K, Miyoshi T et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010; 55 (10): 976-82.Hirohata A, Yamamoto K, Miyoshi T et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010; 55 (10): 976-82.Scholze J.R, Schaefer A, Kreutz R. Safety and efficacy of olmesartan: an observational pooled - analysis of 156 682 hypertensive patients. Expert Opin Drug Saf 2011.Scholze J.R, Schaefer A, Kreutz R. Safety and efficacy of olmesartan: an observational pooled - analysis of 156 682 hypertensive patients. Expert Opin Drug Saf 2011.

The authors declare that there are no conflicts of interest present.